Aldeyra Therapeutics (NASDAQ:ALDX) Stock: Insider Richard Douglas Buys 200,000 Shares

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Director Richard Douglas acquired 200,000 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was purchased at an average price of $0.64 per share, with a total value of $128,000.00. Following the transaction, the director owned 395,000 shares in the company, valued at $252,800. This represents a 102.56% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Aldeyra Therapeutics Stock Up 3.1%

Aldeyra Therapeutics stock traded up $0.02 during mid-day trading on Friday, hitting $0.65. 733,835 shares of the company’s stock were exchanged, compared to its average volume of 1,710,354. The firm has a market capitalization of $39.23 million, a P/E ratio of -2.03 and a beta of 1.32. Aldeyra Therapeutics, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $5.93. The company’s 50 day simple moving average is $0.99 and its 200-day simple moving average is $2.12.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, November 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05. Research analysts expect that Aldeyra Therapeutics, Inc. will post -0.27 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday, September 29th. HC Wainwright restated a “neutral” rating and set a $2.00 target price on shares of Aldeyra Therapeutics in a report on Wednesday, September 30th. Wall Street Zen lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings cut shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, September 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Aldeyra Therapeutics has an average rating of “Hold” and an average price target of $2.00.

Hedge Funds Weigh In On Aldeyra Therapeutics

A number of large investors have recently added to or reduced their stakes in ALDX. BlackRock Inc. bought a new stake in shares of Aldeyra Therapeutics in the second quarter valued at about $2,678,000. GSA Capital Partners LLP bought a new position in shares of Aldeyra Therapeutics during the second quarter worth about $1,007,000. Renaissance Technologies LLC grew its holdings in shares of Aldeyra Therapeutics by 146.6% during the first quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company’s stock worth $1,459,000 after buying an additional 513,187 shares in the last quarter. Bank of New York Mellon Corp raised its position in Aldeyra Therapeutics by 18.1% in the 1st quarter. Bank of New York Mellon Corp now owns 136,746 shares of the biotechnology company’s stock valued at $231,000 after buying an additional 20,980 shares during the last quarter. Finally, Hikari Power Ltd acquired a new stake in Aldeyra Therapeutics in the 2nd quarter valued at approximately $43,000. Institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company’s research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra’s investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.